Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ProPhase Labs (PRPH) EBT: 2010-2025

Historic EBT for ProPhase Labs (PRPH) over the last 16 years, with Sep 2025 value amounting to -$7.0 million.

  • ProPhase Labs' EBT rose 6.38% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.4 million, marking a year-over-year increase of 0.56%. This contributed to the annual value of -$42.3 million for FY2024, which is 88.99% down from last year.
  • According to the latest figures from Q3 2025, ProPhase Labs' EBT is -$7.0 million, which was down 89.44% from -$3.7 million recorded in Q2 2025.
  • ProPhase Labs' 5-year EBT high stood at $15.9 million for Q1 2022, and its period low was -$19.0 million during Q4 2024.
  • In the last 3 years, ProPhase Labs' EBT had a median value of -$7.0 million in 2025 and averaged -$7.3 million.
  • In the last 5 years, ProPhase Labs' EBT tumbled by 2,092.86% in 2021 and then soared by 1,405.20% in 2022.
  • ProPhase Labs' EBT (Quarterly) stood at $9.6 million in 2021, then slumped by 153.93% to -$5.2 million in 2022, then plummeted by 117.06% to -$11.3 million in 2023, then crashed by 68.84% to -$19.0 million in 2024, then rose by 6.38% to -$7.0 million in 2025.
  • Its last three reported values are -$7.0 million in Q3 2025, -$3.7 million for Q2 2025, and -$4.7 million during Q1 2025.